A new review suggests that looking at immune checkpoints as a dynamic system, rather than isolated markers, could improve how doctors predict both the benefits and risks of cancer immunotherapy. The review focuses on inhibitory receptors like PD-1, CTLA-4, LAG-3, TIM-3, TIGIT, VISTA, and NKG2A, which are proteins on immune cells that can dampen the immune response. Current biomarkers, such as PD-L1 expression, mismatch-repair deficiency, and tumor mutational burden, offer limited guidance on immune-related adverse events (irAEs), which are side effects caused by the immune system attacking healthy organs.
The authors propose that by distinguishing between different states of these receptors, such as those that can be "reinvigorated" to fight cancer versus those that are permanently dysfunctional or prone to causing autoimmunity, doctors could better select patients for immunotherapy, tailor treatment regimens, and monitor for early signs of toxicity. This multi-parameter approach could also help in using combination immunotherapy more precisely.
It is important to note that this is a theoretical framework, not a clinical study. The review does not provide new trial data or statistical evidence for the proposed models. The ideas are based on a synthesis of existing research and are meant to guide future investigation.
For patients, this means that while current immunotherapy is effective for many, predicting who will experience severe side effects remains a challenge. This new way of thinking could eventually lead to more personalized and safer treatment strategies, but more research is needed before it can be used in everyday practice.
